No, you cannot give TNK (tenecteplase) to a patient with massive pulmonary embolism if they have an intracranial arteriovenous malformation.
Intracranial arteriovenous malformation is an absolute contraindication to tenecteplase administration 1. The FDA drug label explicitly lists "intracranial or intraspinal...arteriovenous malformation" as a contraindication to TNKase, and the 2025 ACR guidelines state that "intracranial hemorrhage is an absolute contraindication to the use of systemic thrombolysis" 2.
Why This Matters for Massive PE
In massive PE with sustained hypotension, you face a life-threatening situation where systemic thrombolysis would normally be first-line therapy. However, the presence of an intracranial AVM fundamentally changes the risk-benefit calculation:
- AVMs carry a 2-4% annual hemorrhage risk 3, but thrombolytic agents dramatically amplify this risk
- Fatal intracranial hemorrhage has been documented when thrombolytics were given to patients with AVMs 4
- The 2014 ESC guidelines report intracranial bleeding rates of 1.9-2.2% even in patients WITHOUT vascular malformations 5
Alternative Management Strategies
When systemic thrombolysis is contraindicated in massive PE, pursue these options in order:
1. Surgical Embolectomy (Preferred)
- Does NOT require systemic thrombolysis
- Can be performed with careful intraoperative anticoagulation management
- The 2025 ACR guidelines note that while surgical embolectomy requires "intraoperative high-dose systemic anticoagulation," this is fundamentally different from systemic thrombolysis and carries lower hemorrhagic risk 2
2. Catheter-Directed Mechanical Thrombectomy
- Mechanical techniques WITHOUT adjunctive thrombolytics have been shown effective in reducing RV/LV ratio with minimized bleeding risk 2
- Specifically designed for high-bleeding-risk patients
3. Extracorporeal Membrane Oxygenation (ECMO)
- Emerging as a therapeutic option for patients with high bleeding risk 2
- Requires full anticoagulation for circuit patency, but this is manageable and reversible
- Can serve as bridge to definitive therapy or stand-alone treatment
4. Anticoagulation Alone
- In the absence of other options, therapeutic anticoagulation may be the only feasible approach
- Accept higher mortality risk from PE to avoid catastrophic intracranial hemorrhage
The Evidence Nuance
There is one case report of successful alteplase use for massive PE in a patient with a known cerebral AVM 6, 4. However:
- This represents a single anecdotal case, not evidence sufficient to override FDA contraindications
- The 2007 Stroke guidelines acknowledge this case but emphasize that "the true risk of thrombolysis-precipitated intracranial hemorrhage is unknown" and that decisions "should be individualized" 4
- Two other reports document fatal intracranial hemorrhage from AVMs after receiving alteplase 4
- Recent 2026 case reports continue to document severe CNS hemorrhages with tenecteplase, including simultaneous intracranial and spinal hemorrhage 7
Critical Pitfall to Avoid
Do not rationalize thrombolytic use based on the single positive case report. The FDA contraindication exists because the hemorrhagic risk is unacceptably high and unpredictable. The mortality from massive PE, while substantial, must be weighed against the near-certain catastrophic outcome of AVM rupture with hemorrhagic stroke during thrombolysis.
Your immediate action: Activate your cardiac surgery team for emergent surgical embolectomy or interventional radiology for mechanical thrombectomy while providing hemodynamic support with vasopressors. If neither is available, consider emergent transfer to a center with these capabilities, using ECMO for transport if necessary.